Kilroy Realty Corp
Cerrado
SectorInmobiliario
36.91 -0.51
Resumen
Variación precio
24h
Mínimo
36.5
Máximo
37.55
Ingresos | -295M -19M |
|---|---|
Ventas | -2.2M 270M |
P/B Media del Sector | 20.219 50.069 |
BPA | 0.16 |
Rentabilidad por dividendo | 5.87 |
Margen de beneficios | -7.135 |
Empleados | 241 |
EBITDA | -65M 118M |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 Meses | +2.38% upside |
Rentabilidad por dividendo Media del Sector | 5.87% 6.28% |
|---|---|
Próximas Ganancias | 27 jul 2026 |
Fecha Próximo Dividendo | 8 jul 2026 |
Próxima Fecha de Ex Dividendo | 30 jun 2026 |
Capitalización Mercado | 530M 4.3B |
|---|---|
Apertura anterior | 37.42 |
Cierre anterior | 36.91 |
Noticias sobre sentimiento de mercado
By Acuity
100%
0%
154 / 167 Clasificación en Real estate
Kilroy Realty Corp Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Kilroy Realty Corp
Kilroy Realty Corporation (NYSE: KRC, the "Company", "Kilroy") is a leading U.S. landlord and developer, with operations in San Diego, Los Angeles, the San Francisco Bay Area, Seattle, and Austin. The Company has earned global recognition for sustainability, building operations, innovation, and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the Company's approach to modern business environments helps drive creativity and productivity for some of the world's leading technology, entertainment, life science, and business services companies. The Company is a publicly traded real estate investment trust ("REIT") and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring, and managing office, life science, and mixed-use projects. As of June 30, 2024, Kilroy's stabilized portfolio totaled approximately 17.0 million square feet of primarily office and life science space that was 83.7% occupied and 85.4% leased. The Company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 92.8%. In addition, the Company had two in-process life science redevelopment projects totaling approximately 100,000 square feet with total estimated redevelopment costs of $80.0 million, and one approximately 875,000 square foot in-process development project with a total estimated investment of $1.0 billion.